Friday, May 24, 2013
Submit a News Story
Imaxio Acquires Orphan Drug Indicated for a Congenital Metabolic Disease
Published: Tuesday, January 22, 2013
Last Updated: Tuesday, January 22, 2013
This acquisition strengthens Imaxio’s pharmaceutical range, which now includes two products sold in France and will finance the development of its vaccine candidates.
Full access to this article is for registered users only.
is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.
Results of the ROTAVAC Rotavirus Vaccine Study in India
Statement of Anthony S. Fauci, M.D. Director, National Institute of Allergy and Infectious Diseases National Institutes of Health.
BBSRC is Major Partner in Europe-wide Synthetic Biology Funding
BBSRC is contributing €3M as a major partner in a new call for research projects in Synthetic Biology.
Cobra Biologics and Vaccibody Sign Agreement to Manufacture DNA Vaccine
Companies announce agreement to manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies.
Cocaine Vaccine Passes Key Testing Hurdle
New anti-cocaine vaccine research shows drug can't reach the brain, human clinical trials on the horizon.
Vectura Establishes Strategic Partnership (Kinnovata) for New Respiratory Business in China
Kinnovata to commercialise products in fast growing Asian respiratory markets.
NIH Scientists Create New Tool for Identifying Powerful HIV Antibodies
It is believed that this latest advance could speed HIV vaccine research.
Bird Flu Expert Working on Vaccine that Protects Against Multiple Strains
As the bird flu outbreak in China worsens, a Purdue University expert is working on vaccines that offer broader protection against multiple strains of the virus.
GSK and Save the Children Partner to Help Africa
Currently, nearly 7 million children under five die every year from preventable diseases.
H7N9: A Novel Influenza Virus and it’s Control
Whilst the virus remains as one primarily circulating in birds, breaking this cycle of replication is the only effective response to its control.
Genome Sequencing Provides Unprecedented Insight into Causes of Pneumococcal Disease
Technology will allow better surveillance of bacterial populations, understanding of vaccine effectiveness.
Advertise On This Site
Terms & Conditions
©2013 Technology Networks
, all rights reserved.